PCSK9及其抑制剂在肝癌治疗中的研究进展
Research Progress of PCSK9 and Its Inhibitors in the Treatment of Hepatocellular Carcinoma
DOI: 10.12677/pi.2026.152014, PDF,    科研立项经费支持
作者: 刘亚峰, 杨 敏, 张 旋*：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南省现代生物医药产业学院，云南 昆明
关键词: 前蛋白转化酶枯草溶菌素9；脂质代谢；肝癌；免疫；PCSK9； Lipid Metabolism； Liver Cancer； Immune
摘要: 前蛋白转化酶枯草溶菌素9 (PCSK9)是胆固醇代谢调控的关键分子，可以降解低密度脂蛋白受体(LDLR)维持胆固醇稳态。近年来研究显示，PCSK9在肝细胞癌(HCC)中异常高表达，并通过促进肿瘤增殖、侵袭、免疫逃逸及胆固醇代谢重编程等方式驱动肝癌进展，成为连接代谢异常与肝细胞癌的重要靶点。本文系统阐述了PCSK9的生物学功能及其在肝细胞癌发展中的作用机制，重点分析了PCSK9抑制剂在调节代谢、直接抑制肿瘤、重塑免疫微环境及协同增强治疗等方面的抗肿瘤潜力，同时总结了当前研究的局限，展望了未来研究方向，以期为PCSK9抑制剂在肝细胞癌个体化治疗中的临床应用提供理论支撑。
Abstract: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a key molecule in the regulation of cholesterol metabolism, which can degrade Low-Density Lipoprotein Receptor (LDLR) to maintain cholesterol homeostasis. In recent years, studies have shown that PCSK9 is abnormally highly expressed in Hepatocellular Carcinoma (HCC) and drives liver cancer progression by promoting tumor proliferation, invasion, immune escape and cholesterol metabolic reprogramming, thus emerging as an important target linking metabolic disorders and hepatocellular carcinoma. This paper systematically elaborates the biological functions of PCSK9 and its mechanism of action in the development of hepatocellular carcinoma, with a focus on analyzing the anti-tumor potential of PCSK9 inhibitors in regulating metabolism, directly inhibiting tumors, remodeling the immune microenvironment and synergistically enhancing therapy. It summarizes the limitations of current research and prospects future research directions, aiming to provide theoretical support for the clinical application of PCSK9 inhibitors in the individualized treatment of hepatocellular carcinoma.
文章引用：刘亚峰, 杨敏, 张旋. PCSK9及其抑制剂在肝癌治疗中的研究进展[J]. 药物资讯, 2026, 15(2): 112-122. https://doi.org/10.12677/pi.2026.152014

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Varanasi, S.K., Chen, D., Liu, Y., Johnson, M.A., Miller, C.M., Ganguly, S., et al. (2025) Bile Acid Synthesis Impedes Tumor-Specific T Cell Responses during Liver Cancer. Science, 387, 192-201. [Google Scholar] [CrossRef] [PubMed]
[3] 钟琬娟, 杨雨桐, 黄功华, 郑婷婷. 胆固醇代谢在肿瘤微环境中的研究进展[J]. 肿瘤学杂志, 2025, 31(9): 812-820.
[4] 陈田. 标志物AGXT2通过LDLR调控细胞内胆固醇代谢重编程抑制肝癌生长转移的机制研究[D]: [博士学位论文]. 重庆: 重庆医科大学, 2024.
[5] 马琳, 李淑娟. PCSK9: 肿瘤发生和发展中的新兴角色及治疗潜力[J]. 肿瘤, 2025: 1-7.
[6] 金子安, 陈阳. 依洛尤单抗对他汀类药物不耐受的经皮冠状动脉介入术后患者血脂及炎性因子的影响[J]. 心血管病防治知识, 2025, 15(12): 15-18.
[7] 周立强. 依洛尤单抗注射液对急性冠脉综合征患者凝血功能的影响[D]: [硕士学位论文]. 南昌: 南昌大学, 2025.
[8] Pezzoli, A., Abenavoli, L., Scarcella, M., Rasetti, C., Svegliati Baroni, G., Tack, J., et al. (2025) The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels. Medicina, 61, Article No. 387. [Google Scholar] [CrossRef] [PubMed]
[9] Theocharidou, E. and Gossios, T. (2025) Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Digestive Diseases, 26, 392-397. [Google Scholar] [CrossRef] 
[10] 张伟琦, 张婷, 李帅. DCE-MRI参数、血清PCSK9水平与乳腺癌患者病理特征及化疗敏感性的相关性[J]. 沈阳医学院学报, 2025, 27(6): 619-625.
[11] 吴敏敏, 骆婕, 廖凤儿, 郑婷, 范荻, 郭琴. PCSK9通过MAPK/ERK通路促进卵巢癌细胞体外增殖和侵袭的实验研究[J]. 中国病理生理杂志, 2025, 41(3): 444-452.
[12] Weiss, T.S. and Buechler, C. (2025) Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients with Primary and Metastatic Liver Tumors. Anticancer Research, 45, 1171-1180. [Google Scholar] [CrossRef] [PubMed]
[13] Jin, W., Yu, J., Su, Y., Lin, H., Liu, T., Chen, J., et al. (2023) Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-Dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma. International Journal of Biological Sciences, 19, 2270-2288. [Google Scholar] [CrossRef] [PubMed]
[14] 闵茜, 董熠, 刘书平, 李清清. PCSK9抑制剂和HMG-CoA还原酶抑制剂降低乳腺癌发生风险: 代谢介导的孟德尔随机化证据[J]. 临床与病理杂志, 2025, 45(5): 539-550.
[15] 林猷图. 降脂药物靶基因与泌尿及男生殖系统肿瘤风险的关联: 一项药物靶向孟德尔随机化研究[D]: [硕士学位论文]. 海口: 海南医科大学, 2025.
[16] Ma, K., Wang, H., Du, Y., Chen, T., Yang, D., Li, Y., et al. (2025) Mendelian Randomization Assessment of the Genetic Effects of Lipid‐Lowering Drugs on Digestive System Cancers. Food Science & Nutrition, 13, e70293. [Google Scholar] [CrossRef] [PubMed]
[17] He, M., Hu, J., Fang, T., Tang, W., Lv, B., Yang, B. and Xia, J. (2021) Protein Convertase Subtilisin/Kexin Type 9 Inhibits Hepatocellular Carcinoma Growth by Interacting with GSTP1 and Suppressing the JNK Signaling Pathway. Cancer Biology & Medicine, 19, 90-103.
[18] Zhang, S., Zhu, X., Feng, L., Li, X., Liu, X., Sun, H., et al. (2021) PCSK9 Promotes Tumor Growth by Inhibiting Tumor Cell Apoptosis in Hepatocellular Carcinoma. Experimental Hematology & Oncology, 10, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[19] Jacome Sanz, D., Raivola, J., Karvonen, H., Arjama, M., Barker, H., Murumägi, A., et al. (2021) Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 13, Article No. 3727. [Google Scholar] [CrossRef] [PubMed]
[20] Li, T., Wu, R. and Luo, K.Q. (2025) PCSK9 Promotes the Malignancy of Triple‐Negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3. Advanced Science, 12, e2408514. [Google Scholar] [CrossRef] [PubMed]
[21] Ruscica, M., Macchi, C., Gandini, S., Macis, D., Guerrieri-Gonzaga, A., Aristarco, V., et al. (2024) Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study. Cancers, 16, Article No. 1411. [Google Scholar] [CrossRef] [PubMed]
[22] Chen, T., Xiang, L., Zhang, W., Xia, Z. and Chen, W. (2024) AGXT2 Suppresses the Proliferation and Dissemination of Hepatocellular Carcinoma Cells by Modulating Intracellular Lipid Metabolism. Journal of Hepatocellular Carcinoma, 11, 1623-1639. [Google Scholar] [CrossRef] [PubMed]
[23] Boonkaew, B., Satthawiwat, N., Pachane, B.C., Brett, L.M., Tangkijvanich, P. and Ariyachet, C. (2025) Palmitic Acid Reduces LDLR-Dependent Uptake of Macrophage-Derived Extracellular Vesicles by Hepatoma Cells. Non-Coding RNA Research, 13, 71-83. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., et al. (2020) Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature, 588, 693-698. [Google Scholar] [CrossRef] [PubMed]
[25] Yuan, J., Cai, T., Zheng, X., Ren, Y., Qi, J., Lu, X., et al. (2021) Potentiating CD8+ T Cell Antitumor Activity by Inhibiting PCSK9 to Promote LDLR-Mediated TCR Recycling and Signaling. Protein & Cell, 12, 240-260. [Google Scholar] [CrossRef] [PubMed]
[26] Hu, C., Qin, M., Lai, W., Zhou, H., Yuan, C., Liu, Y., et al. (2025) Blocking PCSK9 Suppresses Hepatocellular Carcinoma Immune Escape by Decreasing Fli1-Mediated SPP1 and PD-L1 Expression. Journal for ImmunoTherapy of Cancer, 13, e012586. [Google Scholar] [CrossRef] 
[27] Siddiq A, A. and Martin, A. (2022) Crocetin Exerts Hypocholesterolemic Effect by Inducing LDLR and Inhibiting PCSK9 and Sortilin in HepG2 Cells. Nutrition Research, 98, 41-49. [Google Scholar] [CrossRef] [PubMed]
[28] Li, Y., Chen, Y., Zhao, C., Yang, Y., Zhang, M., Cheng, H., et al. (2024) Arenobufagin Modulation of Pcsk9-Mediated Cholesterol Metabolism Induces Tumor-Associated Macrophages Polarisation to Inhibit Hepatocellular Carcinoma Progression. Phytomedicine, 128, Article ID: 155532. [Google Scholar] [CrossRef] [PubMed]
[29] Qin, W., Yang, Z., Li, M., Chen, Y., Zhao, X., Qin, Y., et al. (2020) High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice. Gastroenterology, 158, 1713-1727. [Google Scholar] [CrossRef] [PubMed]
[30] 杨晓丽, 申志杰, 张瑶, 王友明. PCSK9抑制剂依洛尤单抗对H2O2导致的血管内皮细胞氧化损伤的影响[J]. 西部医学, 2025, 37(2): 191-197.
[31] 王诗淳, 史明慧, 王丹琦, 习舒, 崔金龙, 刘姝言, 袁帅, 靳英辉. PCSK9调控前列腺癌细胞生物学功能和铁死亡敏感性的作用研究[J]. 药物流行病学杂志, 2025, 34(3): 282-292.
[32] Yang, Q., Wang, S., Liu, Y., Song, A., Wu, Z., Wan, S., et al. (2023) Targeting PCSK9 Reduces Cancer Cell Stemness and Enhances Antitumor Immunity in Head and Neck Cancer. iScience, 26, Article ID: 106916. [Google Scholar] [CrossRef] [PubMed]
[33] Li, Y., Zhou, S., Fu, W., Li, X., Chen, T., Le, H., et al. (2025) A Versatile Immunomodulated nanoCRISPR Converter Augments the Susceptibility and Visibility of Tumors to the Immune System. Proceedings of the National Academy of Sciences, 122, e2415100122. [Google Scholar] [CrossRef] [PubMed]
[34] Fang, S., Zheng, L., Shu, G., Xiaoxiao, C., Guo, X., Ding, Y., et al. (2024) Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma. ACS Nano, 18, 8811-8826. [Google Scholar] [CrossRef] [PubMed]
[35] Seidah, N.G. and Prat, A. (2021) The Multifaceted Biology of PCSK9. Endocrine Reviews, 43, 558-582. [Google Scholar] [CrossRef] [PubMed]
[36] Meng, C., Zhang, H., Yi, X., Kong, G., Zhang, X., Wang, B., et al. (2025) Reversal of Tumour Immune Evasion via Enhanced MHC-Class-I Antigen Presentation by a Dual-Functional RNA Regulated System. Molecular Cancer, 24, Article No. 258. [Google Scholar] [CrossRef] 
[37] 张嘉瑜, 朱馨婷, 韩冷, 张正筠, 黄修燕, 张靖, 李婕, 郭澄, 杨全军. 基于肿瘤免疫调控作用的胆固醇代谢研究进展[J]. 重庆医科大学学报, 2025, 50(11): 1500-1505.
[38] Rossi, I., Marodin, G., Lupo, M.G., Adorni, M.P., Papotti, B., Dall’Acqua, S., et al. (2024) Gene Silencing of Angiopoietin-Like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line. International Journal of Molecular Sciences, 25, Article No. 3708. [Google Scholar] [CrossRef] [PubMed]
[39] 姜文鑫, 刘鹏. 肿瘤免疫治疗与脂质代谢异常[J]. 肿瘤防治研究, 2025, 52(5): 355-360.
[40] Xu, W., Hu, M., Lu, X., Lao, Y., Ma, N., Wang, Y., et al. (2024) Inhibition of PCSK9 Enhances the Anti-Hepatocellular Carcinoma Effects of TCR-T Cells and Anti-Pd-1 Immunotherapy. International Journal of Biological Sciences, 20, 3942-3955. [Google Scholar] [CrossRef] [PubMed]
[41] Sun, P., Han, F., Li, X., Wu, C., Deng, T., He, J., et al. (2025) Silencing PCSK9 Reshapes the Spatiotemporal Activation of STING for Safe and Effective Cancer Immunotherapy. Nature Communications, 16, Article No. 11622. [Google Scholar] [CrossRef] 
[42] Zhang, X., Zhao, W., Nguyen, G.N., Zhang, C., Zeng, C., Yan, J., et al. (2020) Functionalized Lipid-Like Nanoparticles for in Vivo mRNA Delivery and Base Editing. Science Advances, 6, eabc2315. [Google Scholar] [CrossRef] [PubMed]
[43] Patrono, C. and Volpe, M. (2021) PCSK9 Inhibition: Not Just LDL-Cholesterol Knock Down: A Glimmer for Cancer. European Heart Journal, 42, 1130-1131. [Google Scholar] [CrossRef] [PubMed]
[44] Yuan, C., Hu, C., Zhou, H., Liu, W., Lai, W., Liu, Y., et al. (2025) L-Methionine Promotes CD8+ T Cells Killing Hepatocellular Carcinoma by Inhibiting NR1I2/PCSK9 Signaling. Neoplasia, 64, Article ID: 101160. [Google Scholar] [CrossRef] [PubMed]
[45] 虞燕波, 支德源. PCSK9抑制剂的应用与消化道肿瘤之间的因果关系: 一项药物靶向孟德尔随机化研究[J]. 临床和实验医学杂志, 2024, 23(22): 2353-2356.
[46] Lao, M., Zhang, X., Li, Z., Sun, K., Yang, H., Wang, S., et al. (2025) Lipid Metabolism Reprograming by SREBP1‐PCSK9 Targeting Sensitizes Pancreatic Cancer to Immunochemotherapy. Cancer Communications, 45, 1010-1037. [Google Scholar] [CrossRef] [PubMed]
[47] Mehranzadeh, E., Crende, O., Badiola, I. and Garcia-Gallastegi, P. (2022) What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors? Biomedicines, 10, Article No. 3292. [Google Scholar] [CrossRef] [PubMed]
[48] Rimbert, A., Smati, S., Dijk, W., Le May, C. and Cariou, B. (2021) Genetic Inhibition of pcsk9 and Liver Function. JAMA Cardiology, 6, 353-354. [Google Scholar] [CrossRef] [PubMed]
[49] Klose, G., Gouni-Berthold, I. and März, W. (2023) Primary Disorders of Lipid Metabolism: Their Place in Current Dyslipidemia Guidelines and Treatment Innovations. Die Innere Medizin, 64, 895-906. [Google Scholar] [CrossRef] [PubMed]
[50] Sun, Y., Zhang, H., Meng, J., Guo, F., Ren, D., Wu, H., et al. (2022) S-Palmitoylation of PCSK9 Induces Sorafenib Resistance in Liver Cancer by Activating the PI3K/AKT Pathway. Cell Reports, 40, Article ID: 111194. [Google Scholar] [CrossRef] [PubMed]
[51] 杨明明, 陈忱. 小核酸药物的研究进展[J]. 微生物学免疫学进展, 2024, 52(5): 77-85.